ACM
LCTX icon

Aster Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Aster Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-218,241
Closed -$198K – 1188
2025
Q2 		$198K Buy
+218,241
New +$129K 0.04% 378

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aster Capital Management's LCTX Position: Q3 2025 in Review

Aster Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2025, closing a stake of 218,241 shares — an estimated $198K sold.

Aster Capital Management first reported a position in LCTX in Q2 2025 and held it in 1 quarter. The position peaked at $198K in Q2 2025. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

  • Aster Capital Management reported no remaining Lineage Cell Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Aster Capital Management sold 218,241 Lineage Cell Therapeutics shares in Q3 2025, an estimated $198K.
  • Aster Capital Management first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 1 quarter.
  • Aster Capital Management's Lineage Cell Therapeutics position peaked at $198K in Q2 2025.
  • 112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on Aster Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.